We’re thrilled to share the presentation delivered by Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, Guest Speaker at the recent 8th Annual DDR Inhibitors Summit.
Lisa’s presentation “Exploring Next-Gen PARP Inhibitors without PARP Trapping” focused on preclinical features and preliminary clinical data of the highly unique non-trapping, PARP1 selective inhibitor NMS-293. Exploiting the high brain penetration of the drug, NMS-293 is currently being explored in adult patients with recurrent high-grade gliomas who failed prior standard of care with temozolomide showing preliminary signs of activity. Notably, clinical safety data available so far fully supports the therapeutic hypothesis that a non-trapping PARP-1 selective inhibitor can be combined with chemotherapy such as temozolomide. NMS-293 is emerging as an ideal partner for combination with DNA-damaging agents like chemotherapies or ADC payloads or with DNA damage repair inhibitors (for example ATR, ATM, WEE1 or PolTheta inhibitors), and is paving the way for additional combination studies in indications outside of BRCA mutant tumors.
NMS is expanding clinical development of NMS-293. As announced on January 13, the FDA has granted approval to proceed with two clinical studies in the relapse setting for small cell lung cancer and BRCA wild-type ovarian cancer. (Press Release)
These important milestones bring the company closer to advancing this PARP1-selective, non-trapping, brain penetrant inhibitor NMS- 293 and potentially transforming the treatment landscape for patients.
